MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HeartFlow Moves Past Canceled SPAC and Appoints CEO

Image courtesy of Artur Szczybylo / Alamy Stock Photo IMG_2022-3-1-140459.jpg
The Redwood City, CA-based company said it has appointed John Farquhar as its president and CEO.

HeartFlow is definitely moving past the termination of its merger with Longview Acquisition Corporation, that occurred last month. The Redwood City, CA-based company is ready to appoint new leadership now that the special purpose acquisition corporation merger is in its rearview mirror.

John Farquhar has been appointed President and CEO and has served as HeartFlow’s President and a member of the board since Jan. 1, 2022.  The company said John Stevens, MD.will continue to serve on the Board of Directors as Vice Chair.

Farquhar has more than 20 years of experience in key leadership roles, providing strategic oversight, driving outstanding performance and delivering operational excellence. Prior to joining HeartFlow in August 2021 as COO, he served as Vice President and General Manager of Medtronic’s Aortic business.

“The leadership transition comes at the right time as the company is at an important inflection point. I am confident that John Farquhar’s relentless focus on our patients and customers, proven leadership, and strong track record of operational excellence will enable the company to accelerate broader access to the AI-driven HeartFlow Analysis and introduce game-changing product innovations such as the PreRead anatomic assessment and Plaque technology,” said William C. Weldon, Chairman, Board of Directors, HeartFlow.

HeartFlow was launched nearly 12 years ago. The company’s core product, the HeartFlow FFRCT Analysis, is a non-invasive cardiac test for stable symptomatic patients with coronary artery disease (CAD).

With the HeartFlow FFRCT Analysis, the company said it currently targets a $10 billion total addressable market opportunity that it plans to expand to more than $50 billion through the introduction of new products, new customer site additions and increased utilization of HeartFlow in existing healthcare systems over the coming years.

The company was on the verge of going public through a SPAC until both it and Longview mutually ended the merger citing unfavorable market conditions. The deal was first announced in July of 2021.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.